Heart Valve Devices | MedTech 360 | Market Analysis | US | 2019
|発行||Millennium Research Group - DRG||商品コード||244581|
|米国の人工心臓弁市場の分析 Heart Valve Devices | MedTech 360 | Market Analysis | US | 2019|
|出版日: 2018年11月30日||ページ情報: 英文||
米国の人工心臓弁市場は世界でも有数の規模で、成長率も高くなっています。特に、経カテーテル心臓弁 (THV) の普及・改良や、人口高齢化が市場成長に大きく貢献しています。技術力のある小規模企業が買収される事例が増える一方、新製品を開発した企業の新規参入も数多く、市場競争は激しさを増しています。
当レポートでは、米国における人工心臓弁の市場について分析し、市場全体および製品カテゴリー別の市場規模見通し (今後10年間分) や、関連疾患の発症状況、市場の背景事情、競争状況 (市場シェア構造など)、市場の将来展望などを調査しております。
The US heart valve device market is large and growing, driven by the continued adoption and launch of THV devices, as well as an aging population. The accumulation of positive clinical trial data is also driving the uptake of THV devices into populations usually treated with surgical devices or were not treated with device intervention. The competitive landscape for the heart valve market continues to shift: small companies with unapproved, innovative devices are acquired by established market players, whereas new competitors and novel types of THV devices are expected to become available in coming years.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for heart valve devices in the US across a 10-year period.
How does this influence the competitiveness of Boston Scientific's entrance into the TAVR market in 2019?
What is the expected uptake of cerebral EPD's in the US market?
What additional US patient populations are now accessible by the positive COAPT trial results?
How does this influence the uptake of other TMVR devices that are expected to earn FDA approval over the forecast period?
When are TMVI devices expected to enter the US market? Which company is most likely to be first to earn FDA approval?
How will TMVI coexist with TMVR?
How will the development of the transcatheter mitral valve device market affect the development of the future TTVR market?
How will the new transcatheter technologies affect the surgical repair and replacement device markets?
What are some strategies that manufacturers have used to mitigate the impact of THV devices on surgical heart valve product lines?
How will the future availability of TTVR devices affect surgical tricuspid repair procedures?
Author(s): Erik J. Bracciodieta, MBiotech
Erik J. Bracciodieta is a senior analyst within the Cardiovascular Medtech Insights team, specializing in cardiac rhythm management and structural heart closure device markets, as well as medical device pricing and regulations in Japan. Erik holds a Master's degree in Biotechnology from the University of Toronto.